80% of Julphar’s products are exported outside the UAE

Gulf Pharmaceutical Industries (Julphar) has established itself as one of the most prominent national companies, contributing to the advancement and leadership of the country’s pharmaceutical industry and has successfully transformed itself in 44 years into one of the largest pharmaceutical manufacturers in the Middle East and Africa, with 80% of the company’s products exported outside the UAE.

With 12 internationally accredited manufacturing plants producing up to 500,000 packs of medicines per day for distribution in more than 40 countries across five continents, Julphar has been considered one of the world’s largest producers of “Insulin” since 2012. It has some of the latest biotech facilities in the UAE. Julphar has approximately 3,400 employees, a clear testament to the UAE’s human, technological, scientific and logistical capabilities that enable it to excel in this industry.

Basil Ziadeh, CEO of Julphar, confirmed that the company is achieving sustainable growth at all levels, noting that the company currently has a strong distribution network that includes more than 280 pharmacies across the GCC countries, which is considered one of the largest insulin manufacturers in the world and the only one in the UAE.

He said 80 per cent of the company’s products are exported outside the UAE, while more than 100 new products are being developed to reinforce its approach of providing high-quality healthcare solutions at affordable prices.

Along the way, Juhua has made many achievements, including the establishment of distribution agents in major global markets in 1990, the opening and operation of three factories, “Juhua 2”, “Juhua 3” and “Juhua 4” in 1998. In 2003, the first active pharmaceutical ingredient factory “Julphar 7” in the field of biotechnology was established, and in 2007, the injection and semi-solid material factories “Julphar 6”, “Julphar 9” and “Julphar 10” were launched.